Table 5.
Univariate and multivariate analysis of risk factors for overall survival.
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| H.R | 95% CI | P-value | H.R | 95% CI | P-value | |
| Gender (M vs F) | 1.50 | 0.53-4.4 | 0.436 | |||
| Age (≥50 vs<50) | 0.66 | 0.35-1.25 | 0.202 | |||
| ECOG PS(0-1vs 2) | 5.16 | 2.46-10.8 | <0.001 | 0.223 | 0.11-0.48 | <0.001 |
| BCLC (B vs C) | 0.99 | 0.49-2.00 | 0.97 | |||
| Child-Pugh (A vs B) | 2.90 | 1.29-6.54 | 0.010 | 0.57 | 0.25-1.33 | 0.192 |
| HBV (yes vs no) | 0.68 | 0.29-1.59 | 0.373 | |||
| Liver cirrhosis (yes vs no) |
0.93 | 0.41-2.1 | 0.866 | |||
| Microvascular invasion (yes vs no) | 1.11 | 0.62-2.0 | 0.727 | |||
| Extrahepatic spread (yes vs no) |
1.16 | 0.59-2.28 | 0.668 | |||
| AFP (≥400μg/L vs <400μg/L) |
1.94 | 0.99-3.30 | 0.048 | 0.65 | 0.33-1.29 | 0.218 |
| Combination of TACE (yes vs no) |
0.932 | 0.487-1.786 | 0.833 | |||
| Treatment option (PL vs PR) |
0.9 | 0.45-1.79 | 0.764 | |||
H.R, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance status; AFP, alpha fetoprotein; BCLC, Barcellona Clinic Liver Cancer; HBV, hepatitis B virus; TACE, transarterial chemoembolization.